Drug intelligence / Profile preview

CAR-NK-CD19 (f402d2)

Development stage: Unknown
Lead developer: Union Hospital of Huazhong University of Science and Technology
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**CAR-NK-CD19** is an investigational, allogeneic cord blood-derived natural killer cell therapy engineered with an anti-CD19 chimeric antigen receptor and interleukin-15 expression cassette. The product is intended to recognize CD19-positive B-cell malignancies and induce NK-cell-mediated cytotoxicity, while IL-15 is intended to support NK-cell persistence and activity. It is being evaluated in a Phase 1 single-center study for relapsed or refractory CD19-positive acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.

Other names: anti-CD19 CAR-engineered NK cellsanti-CD-19 CAR-engineered NK cellsanti-CD 19 CAR-engineered NK cellsanti-CD19 CAR-modified NK cellsanti-CD-19 CAR-modified NK cellsanti-CD 19 CAR-modified NK cellsCAR-NK-CD19CAR-NK-CD-19CAR-NK-CD 19CAR-NK-CD19 cellsCAR-NK-CD-19 cellsCAR-NK-CD 19 cellscord blood-derived anti-CD19 CAR-engineered NK cells

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CAR-NK-CD19 (f402d2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAR-NK-CD19 (f402d2).

Explore the full profile